Imatinib Accord

Imatinib, the active ingredient in Imatinib Accord, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is used to treat certain blood cancers and solid tumors, including chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor, in adult patients.

GNH USA supplies Imatinib Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies, clinics and research institutions worldwide, with a focus on quality and regulatory compliance.

Imatinib is indicated for malignancies driven by BCR‑ABL, c‑KIT or PDGFR tyrosine‑kinase pathways.

- Chronic myeloid leukemia (CML): achieves disease control by reducing leukemic cell proliferation. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): helps induce remission in affected patients. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth and progression.

Imatinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: swelling of hands, feet or face. - Muscle cramps or pain. - Fatigue or weakness.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe neutropenia or thrombocytopenia: marked reduction in blood cell counts. - Cardiac failure or pulmonary hypertension: signs of heart or lung vascular compromise.

Before initiating therapy, clinicians should evaluate several safety parameters and follow specific handling guidelines.

- Monitor blood counts: perform regular complete blood count tests to detect cytopenias. - Assess liver function: check hepatic enzymes periodically for signs of toxicity. - Evaluate cardiac status: screen for pre‑existing heart disease or pulmonary hypertension. - Avoid use in patients with known hypersensitivity to imatinib or its excipients. - Adjust dose in renal impairment: consider renal function when dosing. - Store at room temperature: keep in original container, protect from moisture and light.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - CYP3A4 strong inhibitors (e.g., ketoconazole, clarithromycin): may raise imatinib levels and risk toxicity. - CYP3A4 strong inducers (e.g., rifampicin, carbamazepine): may lower imatinib exposure and reduce efficacy. - Antacids containing aluminum or magnesium: can reduce oral absorption of imatinib.

Moderate Interactions (Monitor Closely): - Warfarin: imatinib may enhance anticoagulant effect, requiring INR monitoring. - Proton pump inhibitors: may modestly decrease imatinib absorption; monitor therapeutic response.